Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Outlook 2025-2034: Trends, Innovations, And Future Outlook

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Size and Projected Growth Rate?
The market for inhibitors of the calcitonin gene-related peptide (CGRP) has seen quick expansion in recent years. Its size is projected to increase from $2.87 billion in 2024 to $3.17 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this historic growth include rising investments in research and development, greater approval of novel drugs, an increasing need for non-opioid pain treatments, and a mounting emphasis on personalized medicine.

The market for inhibitors of the calcitonin gene-related peptide (CGRP) is predicted to experience substantial expansion in the upcoming years. The market's size is projected to surge to $4.68 billion by 2029, maintaining a compound annual growth rate (CAGR) of 10.2%. The expansion expected in the forecast period is due primarily to the rising incidence of migraine, an increase in preventative migraine therapies' usage, heightened patient awareness, and augmented healthcare spending. The forecast period will also be characterized by significant trends such as advancements in drug formulation technology, the incorporation of digital health instruments, advancements in precision medicine, and technological progress in biosimilars.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp

What Are the Major Segments in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The calcitonin gene-related peptide (CGRP) inhibitors market covered in this report is segmented -

1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies

Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp

What Are The Driving Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Evolution?
The growth of the calcitonin gene-related peptide (CGRP) inhibitors market is anticipated to be spurred by the rising frequency of migraine occurrence. Typically presented as a severe headache with throbbing pain usually on one side of the head. Migraines are also frequently accompanied by nausea, vomiting, and sensitivity to light and noise. The surge in migraine occurrence can be attributed to increased levels of stress, considering chronic stress stimulates neural pathways. CGRP inhibitors provide an effective solution for managing migraines by delivering a targeted, preventative approach and compatibility with both immediate and continuous care protocols. They minimize both the frequency and severity of headaches by effectively blocking CGRP receptors, thereby improving personal well-being and everyday functionality. For example, as per the report by the National Library of Medicine, a US-based health information institution, in January 2023, the worldwide occurrence of migraine ranged between 14% and 15%, accounting for 4.9% of the total global disease burden. Hence, the surge in the occurrence of migraines is fuelling the growth of the calcitonin gene-related peptide (CGRP) inhibitors market.

Which Firms Dominate The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Segments?
Major companies operating in the calcitonin gene-related peptide (CGRP) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

What Are the Latest Developing Trends in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Leading businesses within the calcitonin gene-related peptide (CGRP) inhibitors industry are prioritizing the development of groundbreaking products to secure approval. These products, such as calcitonin gene-related peptide (CGRP) receptor antagonists, aim to heighten the effectiveness of migraine treatments as well as broaden therapeutic indications. Additionally, companies are striving to provide more accessible modes of administration like oral and intranasal formulations. Calcitonin gene-related peptide (CGRP) receptor antagonist is medication designed to inhibit the calcitonin gene-related peptide (CGRP) receptor, thus blocking signals of migraine-related pain. For example, in April 2023, AbbVie Inc., an American biotech company, gained FDA approval for QULIPTA (atogepant) prescribed to manage chronic migraine in adults. QULIPTA operates as an oral calcitonin gene-related peptide (CGRP) receptor antagonist and blocks calcitonin gene-related peptide (CGRP) receptors, playing a significant role in the pathophysiology of migraines, and as a result, aids in the prevention of migraine episodes.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/calcitonin-gene-related-peptide-cgrp-inhibitors-global-market-report

Which Is The Largest Region In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
2. What is the CAGR expected in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
3. What Are the Key Innovations Transforming the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Industry?
4. Which Region Is Leading the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.